Rain Therapeutics Inc. (RAIN): Price and Financial Metrics
RAIN Price/Volume Stats
| Current price | $1.21 | 52-week high | $11.32 |
| Prev. close | $1.23 | 52-week low | $0.82 |
| Day low | $1.21 | Volume | 3,706,000 |
| Day high | $1.27 | Avg. volume | 550,818 |
| 50-day MA | $1.16 | Dividend yield | N/A |
| 200-day MA | $2.14 | Market Cap | 44.01M |
RAIN Stock Price Chart Interactive Chart >
Rain Therapeutics Inc. (RAIN) Company Bio
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Latest RAIN News From Around the Web
Below are the latest news stories about RAIN ONCOLOGY INC that investors may wish to consider to help them evaluate RAIN as an investment opportunity.
Rain Oncology to be acquired by Pathos AI for $1.16 in cash per shareMore on Rain Oncology |
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value RightsNEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a “CVR”) for potential cash payments of up to approximately $0.17 per share. The Rain Board of Directors voted unanimously to approve the proposed Offer, Merger and related transactions contemplated by the Merger A |
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business UpdateNEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on the Company’s key developments and business operations. “Rain continues to evaluate a number of strategic opportunities to add value for its stockholders,” said Avanish Vellanki, co-founder and chief executive officer of Rain. “We anticipate being able to provide a public update on our efforts before |
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesNEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain’s programs. Rain’s Board of Directors and management team |
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain |
RAIN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | 13.08% |
| 1-year | -82.44% |
| 3-year | -92.14% |
| 5-year | N/A |
| YTD | 0.83% |
| 2023 | -85.00% |
| 2022 | -37.89% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...